Zylox-Tonbridge Medical Technology Co., Ltd. (FRA:818)
Germany
· Delayed Price · Currency is EUR 2.500
0.00 (0.00%)
At close: Dec 4, 2025
FRA:818 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Revenue | 898.46 | 782.48 | 527.75 | 334.09 | 177.91 | 27.63 | Upgrade
|
| Revenue Growth (YoY) | 35.39% | 48.27% | 57.97% | 87.78% | 543.88% | 461.95% | Upgrade
|
| Cost of Revenue | 256.36 | 222.58 | 142.77 | 81.42 | 46.03 | 11.34 | Upgrade
|
| Gross Profit | 642.09 | 559.9 | 384.99 | 252.67 | 131.88 | 16.29 | Upgrade
|
| Selling, General & Admin | 283.39 | 265.76 | 277.92 | 249.47 | 195.87 | 51.45 | Upgrade
|
| Research & Development | 253.28 | 233.23 | 261.01 | 233.46 | 168.1 | 72.07 | Upgrade
|
| Other Operating Expenses | 5.34 | 1.36 | 1.6 | -6.78 | -13.94 | -9.88 | Upgrade
|
| Operating Expenses | 542.05 | 500.39 | 540.54 | 476.18 | 350.05 | 113.63 | Upgrade
|
| Operating Income | 100.04 | 59.51 | -155.55 | -223.51 | -218.17 | -97.34 | Upgrade
|
| Interest Expense | - | - | - | -0.72 | -0.31 | -0.67 | Upgrade
|
| Interest & Investment Income | 58.93 | 65.17 | 77.79 | 95.57 | 13.09 | 0.36 | Upgrade
|
| Earnings From Equity Investments | - | -1.1 | - | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | -0.21 | 1.51 | -0.26 | 19.63 | -8.28 | -4.47 | Upgrade
|
| Other Non Operating Income (Expenses) | 21.68 | 11.43 | 8.4 | - | - | - | Upgrade
|
| EBT Excluding Unusual Items | 180.44 | 136.51 | -69.63 | -109.04 | -213.66 | -102.12 | Upgrade
|
| Gain (Loss) on Sale of Investments | -27.69 | -36.21 | -8.51 | 4.81 | 13.95 | 1.62 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.16 | -0.05 | -0.59 | -9.32 | 0.02 | 0.03 | Upgrade
|
| Pretax Income | 152.59 | 100.26 | -78.73 | -113.56 | -199.69 | -100.47 | Upgrade
|
| Net Income | 152.59 | 100.26 | -78.73 | -113.56 | -199.69 | -100.47 | Upgrade
|
| Net Income to Common | 152.59 | 100.26 | -78.73 | -113.56 | -199.69 | -100.47 | Upgrade
|
| Shares Outstanding (Basic) | 321 | 323 | 329 | 330 | 295 | 195 | Upgrade
|
| Shares Outstanding (Diluted) | 327 | 328 | 329 | 330 | 295 | 195 | Upgrade
|
| Shares Change (YoY) | -0.26% | -0.22% | -0.51% | 12.15% | 51.26% | 9.59% | Upgrade
|
| EPS (Basic) | 0.48 | 0.31 | -0.24 | -0.34 | -0.68 | -0.52 | Upgrade
|
| EPS (Diluted) | 0.46 | 0.31 | -0.24 | -0.34 | -0.68 | -0.52 | Upgrade
|
| Free Cash Flow | 102.2 | -17.26 | -92.48 | -226.06 | -194.32 | -127.47 | Upgrade
|
| Free Cash Flow Per Share | 0.31 | -0.05 | -0.28 | -0.68 | -0.66 | -0.65 | Upgrade
|
| Dividend Per Share | 0.102 | 0.102 | - | - | - | - | Upgrade
|
| Gross Margin | 71.47% | 71.55% | 72.95% | 75.63% | 74.13% | 58.95% | Upgrade
|
| Operating Margin | 11.13% | 7.61% | -29.48% | -66.90% | -122.63% | -352.29% | Upgrade
|
| Profit Margin | 16.98% | 12.81% | -14.92% | -33.99% | -112.24% | -363.61% | Upgrade
|
| Free Cash Flow Margin | 11.38% | -2.21% | -17.52% | -67.66% | -109.22% | -461.34% | Upgrade
|
| EBITDA | 134.46 | 92.18 | -126.44 | -203.47 | -208.49 | -90.72 | Upgrade
|
| EBITDA Margin | 14.97% | 11.78% | -23.96% | -60.90% | -117.18% | - | Upgrade
|
| D&A For EBITDA | 34.42 | 32.67 | 29.11 | 20.04 | 9.68 | 6.62 | Upgrade
|
| EBIT | 100.04 | 59.51 | -155.55 | -223.51 | -218.17 | -97.34 | Upgrade
|
| EBIT Margin | 11.13% | 7.61% | -29.48% | -66.90% | -122.63% | - | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.